6 articles
Indian shares rose on earnings despite rising Brent crude prices limiting gains amid Middle East tensions. Investors monitor quarterly results from major firms like Reliance and Sun Pharma.
JPMorgan projects rising Indian outbound M&A to secure supply chains, exemplified by Sun Pharma's $11.75 billion Organon deal. Total M&A hit $100 billion in H1 2026, driven by needs for critical miner
Indian shares opened little changed after the Federal Reserve held rates steady, amidst geopolitical risks pushing Brent crude lower. Meanwhile, Sun Pharma gained approval to manufacture semaglutide i
Sun Pharma received South African regulatory approval to manufacture and sell a generic version of semaglutide, challenging Novo Nordisk and Eli Lilly in the diabetes and obesity drug market.
Jefferies reported Q2 profit doubling driven by M&A advisory fees, including advising on Sun Pharma's $11.75B acquisition of Organon and Kelonia's sale to Eli Lilly.
India's Sun Pharmaceutical Industries agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion. The transaction grants Sun Pharma full ownership of the
ChemBrief